CPHI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Home Research & Development News Regeneron and Sanofi announce new Praluent injection analyses presented at AHA scientific sessions 2015
News
11 Nov 2015

Regeneron and Sanofi announce new Praluent injection analyses presented at AHA scientific sessions 2015

74% of patients reached their LDL cholesterol goals on 75 mg dose; Of the remaining patients whose dose was adjusted to 150 mg, most achieved their goal.

Regeneron Pharmaceuticals and Sanofi have announced a new post-hoc analysis of six Phase III clinical trials showing that approximately three quarters (74%) of patients reached their pre-specified LDL cholesterol targets within 8 weeks of adding Praluent (alirocumab) Injection 75 mg to their standard-of-care, which included statins. In the 26% of patients whose dose was increased to 150 mg, most were able to achieve their pre-specified LDL cholesterol target, with an average additional 14% reduction in LDL cholesterol. The results from this and other analyses, which evaluated Praluent every 2 weeks, were presented at the American Heart Association (AHA) Scientific Sessions in Orlando, FL.

"In this analysis of patients who required further improvement of their LDL cholesterol levels, adding Praluent 75 mg to their standard-of-care allowed the majority of patients to achieve their LDL cholesterol goals. For those who required further LDL cholesterol lowering, increasing Praluent to 150 mg provided additional efficacy," said Harold Bays, from the Louisville Metabolic & Atherosclerosis Research Center, Kentucky, US. "Data such as these provide clinicians practical insight as to how the two Praluent doses may better allow patients to achieve their LDL cholesterol goals."

These results are based on a pooled post-hoc analysis of 1,291 patients with high cardiovascular (CV) risk or an inherited form of high cholesterol (heterozygous familial hypercholesterolemia, or HeFH) which found 74% of patients who added Praluent 75 mg achieved their LDL cholesterol-lowering goals at week 8, and the remaining 26% had their dose adjusted to 150 mg at week 12. In other results:

  • By week 24, 61% of patients who switched to 150 mg achieved their goal, with a mean additional LDL cholesterol reduction of 14%

    • .

  • Comparable adverse event (AE) rates were observed in patients whose Praluent dose was increased, versus those whose dose was not (66% in both arms in placebo-controlled trials; and 55% versus 56% respectively in ezetimibe-controlled trials).

  • About the data: The pooled analysis included results from six Phase III ODYSSEY trials where patients added Praluent 75 mg to standard-of-care, and had their dose adjusted at week 12 to 150 mg if they did not reach their LDL cholesterol goals by week 8. Cholesterol goals were either less than 70 mg/dL or less than 100 mg/dL, dependent on CV risk. All patients across the six trials received background statin therapy. In three trials Praluent was compared to placebo (ODYSSEY FH I, FH II, COMBO I), and in three it was compared to ezetimibe (ODYSSEY COMBO II, OPTIONS I, OPTIONS II).

    In a separate pooled post-hoc analysis of 3,499 patients, individuals with diabetes (n=1,051) who initially received Praluent 75 mg or 150 mg every 2 weeks had a mean percent difference in LDL cholesterol of 44% and 58%, respectively, versus placebo at week 24 (p less than 0.0001). In other results:

  • Praluent was generally well tolerated, with the most common adverse events among people with diabetes being nasopharyngitis (11% Praluent, 10% placebo) and upper respiratory tract infection (8% Praluent, 9% placebo).

  • About the data: The pooled analysis included results from five placebo-controlled trials of individuals with diabetes (1,051), and without diabetes (2,448) with inadequately controlled hypercholesterolemia receiving standard-of-care, which included maximally-tolerated statins. In two of the trials, patients initially received Praluent 150 mg (ODYSSEY LONG TERM, HIGH FH). In three of the trials, patients initially received Praluent 75 mg and had their dose adjusted to 150 mg at week 12 if they required additional lipid-lowering to meet their LDL cholesterol goals (ODYSSEY COMBO I, FH I, FH II).

    • A third post-hoc analysis of 4,974 patients did not find an increased risk of diabetes-related AEs among those who didn't have diabetes when they entered the trials, regardless of whether they were taking Praluent or were in a control group (placebo or ezetimibe). There was also no evidence that Praluent affected the incidence of new-onset diabetes or pre-diabetes. The ongoing ODYSSEY OUTCOMES trial will provide further data on the impact of Praluent on glycemic measures.

  • About the data: The pooled analysis included results from 10 Phase III ODYSSEY trials of patients with inadequately controlled hypercholesterolemia, ranging from 24 to 78 weeks (ODYSSEY LONG TERM, FH I, FH II, HIGH FH, COMBO I, COMBO II, OPTIONS I, OPTIONS II, MONO, ALTERNATIVE). In total, 1,526 (31%) had a medical history of diabetes upon entering the trials, 1,969 (40%) were identified as having pre-diabetes, and 1,479 (30%) did not have diabetes (e.g., had a normal concentration of glucose in the blood).

    • Related tags
    Research & Development

    Related News